Literature DB >> 1665111

Effects of ossein-hydroxyapatite compound on ewe bone remodeling: biochemical and histomorphometric study.

P Chavassieux1, P Pastoureau, G Boivin, P D Delmas, M C Chapuy, P J Meunier.   

Abstract

Ossein-hydroxyapatite compound (OHC) is a protein-mineral complex derived from bovine bone. Its effects on bone remodeling were studied in old ewes which have seasonal variations in bone remodeling. Seven animals received 200 mg OHC/kg b.w./day for 90 days from July to September. The control group consisted of 7 untreated animals followed for the same period of time. OHC was administered through a fistula into the fourth stomach. A significant decrease of bone histomorphometric parameter values was noted in controls at the end of the experiment, due to seasonal variations: the cancellous eroded perimeter decreased by 45%, the osteoblastic perimeter by 60% and the bone formation rate at the cell level by 20%. In contrast, in the treated-group, these parameters tended to increase or did not change. In conclusion, counteracting the significant seasonal reduction of bone remodeling in ewes, OHC seems able to stimulate directly or indirectly bone metabolism, especially when osteoblast activity is reduced and may partly prevent the seasonal reduction of bone turnover.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1665111     DOI: 10.1007/bf02208688

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  10 in total

1.  The influence of ossein-hydroxyapatite compound ('Ossopan') on the healing of a bone defect.

Authors:  M Annefeld; R Caviezel; E Schacht; K H Schicketanz
Journal:  Curr Med Res Opin       Date:  1986       Impact factor: 2.580

2.  Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker
Journal:  J Bone Miner Res       Date:  1987-12       Impact factor: 6.741

3.  Double-antibody radioimmunoassay for parathyroid hormone.

Authors:  H H Conaway; C S Anast
Journal:  J Lab Clin Med       Date:  1974-01

4.  Estimation of the three-dimensional wall thickness of completed remodeling sites in iliac trabecular bone.

Authors:  J Kragstrup; H J Gundersen; F Melsen; L Mosekilde
Journal:  Metab Bone Dis Relat Res       Date:  1982

5.  Prospective trial of ossein-hydroxyapatite compound in surgically induced postmenopausal women.

Authors:  J J Stĕpán; J Pospíchal; J Presl; V Pacovský
Journal:  Bone       Date:  1989       Impact factor: 4.398

6.  Specific radioimmunoassay for ovine bone gla-protein (osteocalcin).

Authors:  P Pastoureau; B Merle; P D Delmas
Journal:  Acta Endocrinol (Copenh)       Date:  1988-09

7.  Intermethod variation in bone histomorphometry: comparison between manual and computerized methods applied to iliac bone biopsies.

Authors:  P M Chavassieux; M E Arlot; P J Meunier
Journal:  Bone       Date:  1985       Impact factor: 4.398

8.  Trabecular bone mineralization lag time determined by tetracycline double-labeling in normal and certain pathological conditions.

Authors:  F Melsen; L Mosekilde
Journal:  Acta Pathol Microbiol Scand A       Date:  1980-03

9.  Examination of new bone growth on aluminium oxide implant contact surfaces after oral administration of ossein-hydroxyapatite compound to rats.

Authors:  K H Schmidt; U M Wörner; H J Buck
Journal:  Curr Med Res Opin       Date:  1988       Impact factor: 2.580

  10 in total
  2 in total

1.  Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bone metabolism in women with senile osteoporosis: a randomized, open-label, parallel-group, controlled, prospective study.

Authors:  Manel Ciria-Recasens; Josep Blanch-Rubió; Mónica Coll-Batet; María Del Pilar Lisbona-Pérez; Adolfo Díez-Perez; Jordi Carbonell-Abelló; José Manasanch; Lluís Pérez-Edo
Journal:  Clin Drug Investig       Date:  2011-12-01       Impact factor: 2.859

2.  Prevention of osteoporosis: four-year follow-up of a cohort of postmenopausal women treated with an ossein-hydroxyapatite compound.

Authors:  Antonio Fernández-Pareja; Elena Hernández-Blanco; José Manuel Pérez-Maceda; Vicente José Riera Rubio; Javier Haya Palazuelos; José Manasanch Dalmau
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.